PPD Honored for Employee Development Programs that Deliver Results for Customers
17 Febbraio 2021 - 4:00PM
Business Wire
Training magazine recognizes PPD for innovative
training practices for 10th consecutive year
PPD, Inc. (Nasdaq: PPD) has been recognized for the 10th
consecutive year as one of the leading U.S. businesses for employee
learning and development. PPD was named to Training magazine’s Top
100 list, which honors companies that demonstrate measurable
results from effective employee learning and development tied to
strategic goals.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210217005667/en/
“Earning this recognition for the 10th year in a row underscores
PPD’s commitment to achieving effective training and employee
development outcomes that provide tangible benefit to our customers
and their drug-development initiatives,” said Jay Dixon, senior
vice president of quality and enterprise learning at PPD. “Our
learning culture contributes to making PPD a great company to work
for and helps increase employee engagement and retention, enhancing
continuity in our customers’ important research programs.”
To view a video of Dixon reflecting on this accomplishment,
visit http://bit.ly/3ptYwxQ.
PPD designs, develops and deploys a wide range of employee
learning and performance programs, providing ongoing training and
development that engages employees for optimal performance,
leverages technology, develops staff and measures outcomes.
“PPD’s learning strategy is directly linked with corporate
objectives and is laser-focused to help its business achieve
critical priorities,” said Lorri Freifeld, Training magazine’s
editor-in-chief. “In the last year, the company initiated landmark
project delivery upskilling initiatives to supercharge the
performance of the thousands of its employees delivering clinical
trials. PPD’s training leverages leading-edge technology,
measurement methods and collaboration for optimum learner
experience and engagement.”
This year marks a milestone for PPD as it is the highest ranking
the company has received on Training magazine’s list. Training’s
rankings are based on a variety of benchmarking statistics, such as
total training budget; percentage of payroll; number of training
hours per employee program; goals, evaluation, measurement and
workplace surveys; hours of training per employee annually; and
detailed formal programs.
Employee learning and development at PPD includes leadership and
high-potential development, key talent programs, technical skills,
job-specific training and individual contributor soft skills
training, all of which are integrated and aligned with business
goals and objectives. These initiatives are driven from the highest
levels within PPD and supported by PPD’s global learning council,
an enterprise-wide, cross-functional group of leaders working to
ensure that PPD is a high-performing learning organization.
Rita Bragadesto, PPD principal learning specialist, also was
named a 2020 Top 5 Emerging Training Leader by Training magazine.
The honor recognizes training professionals who have been in the
industry for two to 10 years and have demonstrated exceptional
leadership skills, business savvy and training instincts.
Bragadesto received her award at Training’s virtual ceremony on
Feb. 8.
About PPD
PPD is a leading global contract research organization providing
comprehensive, integrated drug development, laboratory and
lifecycle management services. Our customers include
pharmaceutical, biotechnology, medical device, academic and
government organizations. With offices in 46 countries and more
than 26,000 professionals worldwide, PPD applies innovative
technologies, therapeutic expertise and a firm commitment to
quality to help customers bend the cost and time curve of drug
development and optimize value in delivering life-changing
therapies to improve health. For more information, visit
www.ppd.com.
This news release contains forward-looking statements. These
statements often include words such as “expect,” “believe,”
“project,” “forecast,” “estimate,” “target” and other similar
expressions. Although we believe these forward-looking statements
are based on reasonable assumptions at the time they are made, you
should be aware that many factors could affect our actual financial
results, and therefore actual results might differ materially from
those expressed in the forward-looking statements. Factors that
might materially affect such forward-looking statements include,
but are not limited to, the fragmented and highly competitive
nature of the drug development services industry; changes in trends
in the biopharmaceutical industry; our ability to keep pace with
rapid technological changes that could make our services less
competitive or obsolete; political, economic and/or regulatory
influences and changes; and other factors disclosed under the “Risk
Factors” section in our periodic reports filed with the Securities
and Exchange Commission (SEC), including our latest Annual Report
on Form 10-K and Quarterly Report on Form 10-Q, which is available
on our website at https://investors.ppd.com or the SEC’s website at
www.sec.gov. We assume no obligation and disclaim any duty to
revise or update any forward-looking statements, or make any new
forward-looking statement, whether as a result of new information,
future events or otherwise, except as required by applicable
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210217005667/en/
Media: Nadine Maeser +1 919 456 4425 media@ppd.com
Investors: Tracy Krumme +1 910 558 4186 investors@ppd.com
Grafico Azioni Pharmaceutical Product Developme (NASDAQ:PPDI)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Pharmaceutical Product Developme (NASDAQ:PPDI)
Storico
Da Ott 2023 a Ott 2024